Doberauer C, Niederle N, Schmidt C G
Department of Internal Medicine, West German Tumor Center, University of Essen.
Cancer. 1988 Aug 1;62(3):474-8. doi: 10.1002/1097-0142(19880801)62:3<474::aid-cncr2820620305>3.0.co;2-2.
Ten men with advanced breast cancer were evaluated for response to treatment with the luteinizing hormone-releasing hormone (LH-RH) analogue, buserelin, alone or in combination with the antiandrogen, flutamide. One of five patients receiving buserelin as a single agent had a partial remission lasting 12 months, and with the addition of flutamide, this lasted over 24 additional months. Three patients had stable disease with a median duration of 6 months (range, two to 14). One patient had progressive disease. Of five patients receiving the combination of buserelin and flutamide from the beginning of therapy, four patients had a partial remission with a median duration of over 15 months (range, over five to 16). One patient's disease remained stable for 12 months. Major side effects were hot flushes, loss of libido, and impotence. Buserelin initiates a castration-like endocrine response and has potential in the treatment of men with disseminated breast cancer when used either alone or in combination with flutamide.
对10名晚期乳腺癌男性患者进行了评估，以观察其对促黄体生成激素释放激素（LH-RH）类似物布舍瑞林单独治疗或与抗雄激素药物氟他胺联合治疗的反应。5名单独接受布舍瑞林治疗的患者中有1例部分缓解持续了12个月，加用氟他胺后，缓解持续了另外24个月以上。3例患者病情稳定，中位持续时间为6个月（范围为2至14个月）。1例患者病情进展。在从治疗开始就接受布舍瑞林和氟他胺联合治疗的5例患者中，4例患者部分缓解，中位持续时间超过15个月（范围为超过5至16个月）。1例患者的病情稳定了12个月。主要副作用为潮热、性欲减退和阳痿。布舍瑞林引发类似去势的内分泌反应，单独使用或与氟他胺联合使用时，对转移性乳腺癌男性患者的治疗具有潜力。
